Dr. El Asmar is an Assistant Professor of Medicine at Johns Hopkins University School of Medicine. She serves as the Unit Medical Director for Meyer 8 and Meyer 9. In this role, Dr. El Asmar oversees clinical operations of two of the largest hospitalist units, fosters collaboration amongst the multi-disciplinary team and ensures delivery of high quality, patient-centered care. She also works closely with nursing staff, care management and other team members to enhance communication, standardize and streamline processes within the units. Dr. El Asmar earned her medical degree from the American University of Beirut and completed residency training in internal medicine at the Johns Hopkins Hospital, prior to joining the hospitalist division. Dr. El Asmar brings years of clinical experience and a commitment to excellence in patient care. She is particularly passionate about transitions of care, multi-disciplinary work and advancing quality improvement initiatives. In addition to her role as Unit Medical Director, Dr. El Asmar actively participates in hospital-wide committees focused on patient and staff safety, quality improvement, and utilization management. Dr. Asmar is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top area of expertise is HER2 Negative Breast Cancer.

Dr. Armstrong works primarily in the area of women's malignancies, with a particular emphasis on breast cancer, ovarian cancer and other gynecologic malignancies, and the genetics of breast and ovarian cancer. She directs the medical gynecologic oncology clinical service and oversees therapeutic clinical trials in gynecologic cancers. Dr. Armstrong's clinical focus is on the development of new therapeutic approaches to the treatment of breast cancer and gynecologic malignancies. Particular areas of interest are intraperitoneal therapy in ovarian cancer and targeted biologic therapies. Dr. Armstrong also directs the Kimmel Cancer Center's Breast and Ovarian Cancer Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examination of new strategies for cancer screening and prevention. Dr. Armstrong has lectured locally, nationally and internationally. She is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees and as chair of several clinical trials through this group. She is a representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute. Dr. Armstrong also serves as a representative of Johns Hopkins to the National Cooperative Cancer Network serving on the ovarian cancer and breast cancer risk reduction panels. She has participated as a member of the Cancer Working Group for the Office of Research on Women's Health for the National Institutes of Health, as a scientific reviewer for the breast and ovarian cancer research programs of the Department of Defense and the National Cancer Institute, as a reviewer for the NCI Special Emphasis Panel for Insight Awards to Stamp Out Breast Cancer and as a member of the NCI SPORE Program parent committee. Dr. Armstrong also is co-principal investigator for the NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site (LAPS) at Johns Hopkins, now the major avenue for adult oncology clinical trials in the country. Recent work includes immune checkpoint inhibitor therapy in endometrial cancers with microsatellite instability and PARP inhibition in ovarian cancer. Dr. Armstrong is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, and Ovarian Cancer.

Dr. Amanda Nickles Fader is a professor in the Johns Hopkins Hospital Department of Gynecology and Obstetrics and the Sidney Kimmel Cancer Center. She is the former fellowship director and division director of the Johns Hopkins Kelly Gynecologic Oncology Service and currently is Vice Chair of Gynecologic Surgical Operations and the Director of the Center for Rare Gynecologic Cancers. Additionally, she serves as the 2024-2025 President of the Society of Gynecologic Oncology. Dr. Fader received her undergraduate degree with highest distinction in music (violin performance) and pre-medicine from the University of Virginia. She earned her medical degree from the Medical College of Virginia, and completed her residency in obstetrics and gynecology at the Magee-Women’s Hospital of UPMC in Pittsburgh. Dr. Fader then underwent gynecologic oncology fellowship training at the Cleveland Clinic. She has co-authored more than 230 publications in peer-reviewed medical journals and is recognized as an expert in rare gynecologic tumors, clinical trials and quality and safety in surgery. She has a special interest in uterine serous carcinoma and low-grade serous carcinoma of the ovary and currently serves as the PI or co-PI of three international NRG Oncology clinical trials. Dr. Fader serves as a national board examiner in gynecologic oncology for the American Board of Obstetrics and Gynecology and Associate Editor of the Gynecologic Oncology journal is a member of the Rare Tumor and Uterine Corpus Committees of the NRG/Gynecologic Oncology Group. She is also co-founder of the Society of Gynecologic Oncology BRIDGES Program, a two-year longitudinal clinical trials and career development program for early-career oncologists. She has been the recipient of several research grants and awards for her research, including the Society of Gynecologic Oncology Innovations Award, the Best AAGL Paper in Minimally Invasive Gynecologic Oncology Surgery, a Department of Defense Ovarian Cancer Clinical Trials Academy Leadership Award, and National Cancer Institute Cervical SPORE grant. Dr. Fader is consistently recognized for clinical excellence on lists such as Baltimore magazine’s Top Docs and Castle Connolly’s Top Doctors, and is a recipient of the Top 10 Docs, Compassionate Doctors and Patient Choice Awards from Vitals.com. She has particular expertise with the surgical and medical management of uterine (endometrial), ovarian, cervical and vulvar cancers, as well as the treatment of women who are at high risk for developing a gynecologic malignancy. She has a special interest in caring for patients throughout the entire spectrum of their lives: from preventive oncology — minimizing key risk factors that can lead to gynecologic cancers — to survivorship initiatives addressing all aspects of recovery, including emotional well-being, sexual health and clinical follow-up. Dr. Fader is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ovarian Cancer, Bladder Reconstruction, and Hernia Surgery.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Robyn Gartrell, MD, MS is a physician-scientist and pediatric oncologist who joined the faculty at Johns Hopkins University School of Medicine as Assistant Professor in January 2024. Dr. Gartrell completed her clinical pediatric hematology/oncology fellowship at New York Presbyterian / Columbia University Irving Medical Center (CUIMC), and a postdoctoral fellowship in Immunotherapy and Precision Medicine. She also completed a Master of Science in Patient Oriented Research as well as her first 5 years as faculty at CUIMC. Dr. Gartrell’s primary research focuses on combination approaches including radiation, chemotherapy, and other target agents with immunotherapy to improve response, increase survival, and decrease toxicity for children, adolescents, and young adults with cancer. Her laboratory uses advances in tumor immunology to develop more effective and more personalized therapies using multiplex platforms and immunogenomics to evaluate the tumor microenvironment and determine which pediatric tumor types, and which patients, will respond to immunotherapy. Dr. Gartrell is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Glioma, Diffuse Midline Glioma H3 K27M-Mutant, HER2 Negative Breast Cancer, and Pancreatic Ductal Adenocarcinoma.

Fong W. Liu, M.D., M.P.H., is an assistant professor at the Johns Hopkins University School of Medicine. Her clinical expertise includes gynecologic oncology and general gynecology and obstetrics. Dr. Liu earned her Doctor of Medicine degree from the University of Alabama. She completed her residency in obstetrics and gynecology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Liu then went on to complete her fellowship in gynecologic oncology at the University of California, Irvine. Prior to joining Johns Hopkins, Dr. Liu served as an instructor in the department of obstetrics and gynecology at Beth Israel Deaconess Medical Center. Dr. Liu is also a gynecologic oncologist at the Sandra and Malcolm Berman Cancer Institute at GBMC. Dr. Liu is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Endometrial Cancer, Oophorectomy, and Hernia Surgery.

Kimberly Levinson, M.D., is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her areas of clinical expertise include minimally invasive surgery with both robotic and single incision laparoscopy, ovarian cancer debulking, cervical cancer and dysplasia. Dr. Levinson received her undergraduate degree from Tufts University. She earned her M.D. from the Johns Hopkins University School of Medicine and her M.P.H. from the Johns Hopkins Bloomberg School of Public Health. She completed her medical residency at the Johns Hopkins University School of Medicine and performed a clinical fellowship in gynecologic oncology at Cleveland Clinic. Dr. Levinson has also completed international research at Preventive Oncology International in Peru and the School for International Training in Chile. Dr. Levinson joined the Johns Hopkins faculty in 2014. Her research interests include health care disparities in gynecologic tumors, cervical cancer prevention and treatment, and surgical innovation. She has published numerous manuscripts in gynecologic oncology involving these and other various research topics. Dr. Levinson is currently a principal investigator in the Specialized Program of Research Excellence (SPORE) in Cervical Cancer. In addition, she has a strong commitment to education, and she is the assistant director of the Johns Hopkins residency program and the associate director of the Gynecologic Oncology fellowship. Dr. Levinson is a member of the American College of Obstetricians and Gynecologists, the Society of Gynecologic Oncology, and the American Medical Association. Dr. Levinson was recognized with a Robert B. Hunt Award for Best Paper Published in the Journal of Minimally Invasive Gynecology in 2014. Dr. Levinson is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Endometrial Cancer, Testicular Yolk Sac Tumor, Ovarian Cancer, Hysterectomy, and Lymphadenectomy.

Dr. Melissa Camp is the lead breast surgeon in the Johns Hopkins Kimmel Cancer Center's Breast Program at Green Spring Station. As the lead breast surgeon, Dr. Camp works closely with experts from medical oncology, radiation oncology, imaging and pathology to deliver comprehensive multidisciplinary breast cancer care to patients in a convenient community setting. Dr. Camp specializes in providing compassionate breast cancer treatment, including nipple-sparing mastectomy and breast conservation surgery, and helping newly-diagnosed patients navigate the decision-making process. She sees patients at The Johns Hopkins Hospital and at Johns Hopkins Health Care & Surgery Center - Green Spring Station. Dr. Camp received her bachelor’s degree in biochemistry/molecular biology summa cum laude from Dartmouth College. She graduated from the Johns Hopkins University School of Medicine and went on to complete residencies in general surgery and preventive medicine and to earn a master's degree in public health from the Johns Hopkins Bloomberg School of Public Health. As a member of the American Society of Breast Surgeons and the Society of Surgical Oncology, Dr. Camp has published several peer-reviewed journal articles and has presented her work at national and international medical meetings. Dr. Camp is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Subareolar Abscess, Paget Disease of the Breast, Mastectomy, and Lymphadenectomy.

Jennifer Joh is a General Surgeon in Lutherville, Maryland. Dr. Joh is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Lymphadenectomy, and Mastectomy. Dr. Joh is currently accepting new patients.

Carol Ritter is an Obstetrics and Gynecologist in Towson, Maryland. Dr. Ritter is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Zoon Vulvitis, Pelvic Inflammatory Disease, Angiomyoma, Uterine Fibroids, and Intrauterine Device Insertion. Dr. Ritter is currently accepting new patients.

Michael Schultz is a General Surgeon in Towson, Maryland. Dr. Schultz is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Intraductal Papilloma, and Lymphadenectomy. Dr. Schultz is currently accepting new patients.

Angela Murrell is a Nurse Practitioner in Baltimore, Maryland. Ms. Murrell has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are HER2 Negative Breast Cancer and BRCA Positive Breast Cancer. Ms. Murrell is currently accepting new patients.

Dongyan Liu is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Liu is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are HER-2 Positive Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Pulmonary Embolism. Dr. Liu is currently accepting new patients.

Julia Flukinger is a Radiologist in Baltimore, Maryland. Dr. Flukinger is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Lump, Galactocoele, Breast Infection, and Fibrocystic Breast Disease.

Benjamin Schultz is a General Surgeon in Baltimore, Maryland. Dr. Schultz is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. His top areas of expertise are Breast Enlargement In Males, Breast Cancer, Thrombophlebitis, Lymphadenectomy, and Mastectomy. Dr. Schultz is currently accepting new patients.

Kristen Fernandez is a General Surgeon in Baltimore, Maryland. Dr. Fernandez is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Intraductal Papilloma, and Lymphadenectomy. Dr. Fernandez is currently accepting new patients.

Roisin Connolly is an Oncologist in Baltimore, Maryland. Dr. Connolly is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Tissue Biopsy.

Teresa Diaz-Montes is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Diaz-Montes is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Vulvar Cancer, Hysterectomy, and Ureteroscopy. Dr. Diaz-Montes is currently accepting new patients.

Neil Friedman is a General Surgeon in Baltimore, Maryland. Dr. Friedman is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. His top areas of expertise are Breast Cancer, Intraductal Papilloma, Paget Disease of the Breast, Lymphadenectomy, and Mastectomy. Dr. Friedman is currently accepting new patients.

Dwight Im is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Im is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. His top areas of expertise are Rectocele, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Oophorectomy. Dr. Im is currently accepting new patients.